The U.S. Patent and Trademark Office has granted the first in what the company expects will be a new family of patents protecting its novel topical gel delivery system that allows for greater bioavailability of an active pharmaceutical ingredient (API).

The patent (U.S. Patent No. 9,918,998), entitled Pharmaceutical Tetracycline Composition For Dermatological Use, covers a topical composition comprised of minocycline or another tetracycline-class drug and a method for making such compositions. The patent also covers treatments of dermatological inflammation or infection using a minocycline composition. Current formulations protected by the patent include BPX-01 for the treatment of acne and BPX-04 for the treatment of rosacea.

This is the fourth U.S. patent issuance BioPharmX has received. Three earlier-issued U.S. patents protect the company's encapsulation delivery system, which can isolate the API. The most recent of these patents, U.S. Patent No. 9,901,586, entitled Dosage Form Comprising an Active Ingredient and a Plurality of Solid Porous Microcarriers, was granted Feb. 27.

The US 9,918,998 patent protects tetracycline-class products carried by BioPharmX's innovative delivery system, which for the first time stabilizes and fully solubilizes these drugs to make them effective in a topical formulation. This includes products that use other tetracycline-class drugs as well as combination products that combine antibiotics with other drugs, for example retinoids.

This patent protection is a significant milestone for BioPharmX, said President and Co-founder Anja Krammer. It recognizes that our development of a topical tetracycline- class drug, something that has eluded the pharmaceutical industry since minocycline was first commercially used in the 1970s, is truly unique.

And, like the other patents we hold, it will protect our valuable intellectual property for a substantial length of time, she said. It recognizes the innovative research and development that BioPharmX has successfully completed and ensures that our company and investors will benefit from it as we commercialize our products.

Oral minocycline has been widely used since the 1970s, however oral antibiotics tend to flood the body with medicine and are commonly associated with adverse effects that range from...

To continue reading